CURETIS news, videos and press releases - Page 2
For more news please use our advanced search feature.
CURETIS - More news...
CURETIS - More news...
- Curetis Files for U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens
- Curetis Reports Results of the Annual General Meeting Held on June 27, 2019
- New Data on Curetis’ Unyvero LRT Panel for Pneumonia to be Presented at ASM Microbe 2019
- Curetis Reports Positive Results from Clinical Validation Study for U.S. FDA 510(k) Submission of Unyvero LRT for BAL Samples
- Curetis to Receive Additional EUR 6.5 Million Financing from EIB and Yorkville
- Curetis Announces Financial Results for the First Three Months of 2019
- Curetis to Hold Annual General Shareholders’ Meeting on June 27, 2019
- Curetis (CURE-NL): Partnering drives turn-round
- Press release: Curetis’ Subsidiary Ares Genetics Introduces NGS Services for Pharma and Public Health Sector at Upcoming ECCMID 2019
- Curetis Publishes Full-Year 2018 Financial Results and Updated Guidance for 2019
- Curetis to Publish its Full-Year 2018 Financial Results on April 11, 2019
- Curetis: Study Data Presented at ECCMID 2019 Confirm Clinical Benefits of Unyvero Platform
- Curetis Introduces Unyvero AMR Atlas to Support Adoption of Rapid DNA Testing for Antibiotic Resistance
- Curetis To Attend Key Conferences in the Second Quarter of 2019
- Curetis and Menarini Diagnostics Enter into Strategic Pan-European Exclusive Partnership for the Distribution of Curetis’ Unyvero
- Curetis’ Subsidiary Ares Genetics and QIAGEN Enter into Bioinformatics Partnership to Fight Antimicrobial Resistance
- Curetis’ Partner Beijing Clear Biotech Submits Filing for Unyvero Approval in China
- Curetis’ Unyvero Application Cartridges Receive Regulatory Approvals in Malaysia and Thailand
- Curetis’ Subsidiary Ares Genetics Advances AI-powered Infectious Disease and Antibiotic Resistance Test
- Curetis Sharpens Focus on Near-Term Strategic Value Drivers
- Curetis Announces Financial Results for the First Nine Months of 2018
- Curetis (CURE-NL): Convertible secures room to manoeuvre
- Curetis (CURE-NL): On track to exceed our expectations
- Curetis (CURE-NL): European growth highlights US opportunity
- Curetis (CURE-NL): FDA opens door to opportunity
- Curetis (CURE-NL): Focus on US launch
